CureVac announced a collaboration with myNEO last month to look for neoantigens on the surface of tumor cells in order to develop mRNA-based cancer vaccines. Moderna and BioNTech, and CureVac, are known as the "mRNA Troika". However, the Phase 3 clinical trial of the mRNA COVID-19 vaccine developed by CureVac failed. CureVac has fallen far behind Moderna and BioNTech due to the failure of the...